1. Medtech Insight
  2. >>Business
  3. >>Financing

Syphilis OTC Test Developer NOWDiagnostics Raises $22.5M

 
• By Ryan Nelson

The Series B funding round led by DigitalDx Ventures will support development and commercialization of more than 30 rapid diagnostic tests in NOWDx’s clinical research pipeline, including its First To Know Syphilis OTC test, currently under US FDA De Novo review, which provides at-home results in minutes.

NOWDx entered a de novo classification request to the US FDA for its Syphilis OTC test in January. • Source: Shutterstock

NOWDiagnostics, Inc. aims to accelerate the development and commercialization of at-home diagnostic tests with $22.5m in series B funding, announced on 9 July.

The Springdale, AK-based company’s First To Know Syphilis OTC test is undergoing De Novo review by the US Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Confido CEO Predicts AI For Repetitive Tasks Will Become As Essential To Clinics As Basic Hygiene

 
• By Marion Webb

Confido Health has raised $10m in Series A funding to expand its AI voice agent from patient scheduling into referrals, prescriptions and billing, bringing the total collected to $13m. CEO Chetan Reddy predicts in the next decade, AI use for admin tasks in healthcare will become mainstream.

Backed By $29M, Sunrise Automates Workflow Using AI To Scale Sleep Care Across US

 
• By Shubham Singh

While Sunrise’s main differentiator is a sensor that detects movement of the lower jaw, the company’s growth plan leans heavily on artificial intelligence to make care scalable. In practice, that means AI handles data triage, therapy monitoring and adherence support.

With $3.2M Funding, Sonomind Moves Toward FDA Talks, Eyes De Novo Pathway For US Market Entry

 
• By Shubham Singh

Sonomind’s immediate focus is treatment-resistant depression, but the company sees broader applications for its platform to treat psychiatric conditions such as anxiety, post-traumatic stress disorder and addiction.

Sava Technologies Microsensing Milestone: 10 Days Continuous Wear, No Finger-Prick Calibration

 
• By Natasha Barrow

Sava Technologies has developed a CGM that uses microneedles to accurately measure glucose levels for up to 10 days without finger-prick calibration. The company raised £14.2m in Series A funding to establish in-house manufacturing for faster production.

More from Business

Confido CEO Predicts AI For Repetitive Tasks Will Become As Essential To Clinics As Basic Hygiene

 
• By Marion Webb

Confido Health has raised $10m in Series A funding to expand its AI voice agent from patient scheduling into referrals, prescriptions and billing, bringing the total collected to $13m. CEO Chetan Reddy predicts in the next decade, AI use for admin tasks in healthcare will become mainstream.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.

‘Much-Needed Tool For Large Tissue Biopsy’: Resitu Medical’s Breast Device FDA Authorized

 
• By Natasha Barrow

Resitu Medical has received FDA 510(k) authorization for the RESL09 breast cancer biopsy device. This handheld minimally invasive device excises tissue samples with diameters up to 9 mm and will first reach market in the US. The company plans to expand the tool’s clinical claims and core size range.